Does intravenous sildenafil clinically ameliorate pulmonary hypertension during perioperative management of congenital heart diseases in children? - A prospective randomized study

• DOI: 10.4103/0971-9784.166457
• Publication Date: 2015-10-01T10:37:22Z
• Authors: VipulKrishen Sharma; Saajan Joshi; Ankur Joshi; Gaurav Kumar; Harmeet Arora; Anurag Garg
• Keywords: Group B

<b>Background:</b> Pulmonary hypertension (PHT), if present, can be a significant cause of increased morbidity and mortality in children undergoing surgery for congenital heart diseases (CHD). Various techniques drugs have been used perioperatively to alleviate the effects PHT. Intravenous (IV) sildenafil is one them not many studies validate its clinical use. <b>Aims Objectives:</b> To compare perioperative PaO ₂ - FiO ratio peak filling rate (PFR), systolic pulmonary artery pressure (PAP) aortic (AoP) ratio, extubation time, Intensive Care Unit (ICU) stay between two groups when administered IV during CHDs. <b>Materials Methods:</b> Patients with ventricular septal defects proven PHT, <14 years age, all American Society Anesthesiologists physical status III, cardiac surgery, were enrolled into Group S (IV sildenafil) C (control) over period 14 months, starting from October 2013. Independent <i>t</i>-test Mann-Whitney U-test various parameters groups. <b>Results:</b> PFR was higher throughout, perioperatively, S. PAP/AoP 0.3 0.4 C, respectively. In S, mean group time 7 ± 7.34 h, whereas it 22.1 10.6. Postoperative ICU 42.3 8.8 h 64.4 15.9 <b>Conclusion:</b> sildenafil, CHD having PHT corrective improves only PAP AoP but also reduces postoperative stay.